8-K: Axsome Therapeutics Faces Setback as FDA Issues Refusal to File Letter for Fibromyalgia Drug AXS-14, New Trial Planned

Axsome Therapeutics announced it received a Refusal to File letter from the FDA for its New Drug Application for AXS-14 for fibromyalgia, necessitating an additional controlled trial.

Summary

• Axsome Therapeutics, Inc. received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia.
• The FDA stated that the NDA was not sufficiently complete to permit a substantive review, specifically citing the second of two placebo-controlled trials as inadequate.
• The inadequacy stemmed from the second trial's 8-week primary endpoint and flexible-dose paradigm, while the first trial (12-week endpoint, fixed-dose) was deemed adequate.
• The FDA did not raise any questions regarding the positive results of the studies, both of which met their primary endpoints.
• To address the FDA's feedback, Axsome plans to conduct an additional controlled trial, which will incorporate a fixed-dose paradigm and a 12-week primary endpoint.
• Axsome anticipates initiating this new trial in the fourth quarter of 2025.

Sentiment

Score: 3

Explanation: The Refusal to File letter from the FDA is a significant setback, requiring an additional clinical trial and delaying potential market entry for AXS-14. While the FDA did not question the positive results of the initial trials and provided clear feedback, the need for further trials introduces substantial delays and costs, negatively impacting the near-term outlook for this specific drug candidate.

Positives

• The FDA did not question the positive results of the initial studies, both of which met their primary endpoints for AXS-14.
• The FDA provided clear and specific feedback, which allows Axsome to move expeditiously with the continued development of AXS-14.
• AXS-14 has demonstrated consistent efficacy across a broad range of fibromyalgia symptoms, including significant improvements in pain, function, and fatigue in completed trials.
• Fibromyalgia represents a high unmet medical need, affecting approximately 17 million patients in the U.S. with only three currently FDA-approved pharmacologic treatments.

Negatives

• Axsome Therapeutics received a Refusal to File (RTF) letter from the FDA for its AXS-14 New Drug Application (NDA).
• The FDA deemed the NDA 'not sufficiently complete' for substantive review, specifically finding one of the two pivotal trials inadequate.
• The company is required to conduct an additional controlled trial, which will delay the potential approval and commercialization of AXS-14.

Risks

• The commercial success of the Company's SUNOSI, AUVELITY, and SYMBRAVO products and the ability to obtain additional indications.
• The Company's ability to maintain and expand payer coverage for its products.
• The success, timing, and cost of ongoing and anticipated clinical trials for product candidates, including funding, enrollment pace, and data readouts.
• The Company's ability to fund additional clinical trials to advance its product candidates.
• The timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration (FDA) or other regulatory authority approval for its product candidates.
• The Company's ability to successfully defend its intellectual property or obtain necessary licenses at an acceptable cost.
• The Company's ability to successfully resolve any intellectual property litigation.
• The successful implementation of the Company's research and development programs and collaborations.
• The success of the Company's license agreements.
• The acceptance by the market of the Company's products and product candidates, if approved.
• The Company's anticipated capital requirements and the potential impact on its cash runway.
• The Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales.
• Unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts, or a global pandemic.
• General economic conditions and regulatory developments not within the Company's control.

Future Outlook

Axsome Therapeutics plans to conduct an additional controlled trial for AXS-14, incorporating the FDA's feedback by using a fixed-dose paradigm and a 12-week primary endpoint. This trial is anticipated to be initiated in the fourth quarter of 2025.

Management Comments

• Herriot Tabuteau, MD, Chief Executive Officer of Axsome, stated: "The clear feedback provided by the FDA’s Division of Anesthesiology, Addiction Medicine, and Pain Medicine allows us to move expeditiously with the continued development of this important investigational medicine for the approximately 17 million patients in the U.S. living with fibromyalgia."
• Dr. Tabuteau also commented: "We are well positioned to initiate a new controlled trial that will incorporate the FDA’s feedback by the end of 2025."

Industry Context

Fibromyalgia is a chronic debilitating disorder affecting approximately 17 million Americans, predominantly women, characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment. Treatment options are limited, with only three pharmacologic treatments currently approved by the FDA, indicating a high unmet medical need. AXS-14 aims to address this significant gap in care.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for AXS-14's trial outcomes.
• It highlights that only three pharmacologic treatments are currently FDA-approved for fibromyalgia, suggesting a significant unmet medical need in the market.
• The FDA's feedback on trial design (12-week endpoint, fixed-dose paradigm) aligns with established standards for demonstrating efficacy in chronic conditions.

Stakeholder Impact

• Shareholders: Potential negative impact due to delayed revenue from AXS-14, increased R&D costs for the new trial, and uncertainty regarding future approval.
• Patients (Fibromyalgia): Delayed access to a potential new treatment option (AXS-14) that has shown consistent efficacy in previous trials.
• Employees: Continued work on AXS-14 development, but potential impact on morale due to regulatory setback.

Next Steps

• Axsome Therapeutics will conduct an additional controlled trial for AXS-14.
• The new trial will use a fixed-dose paradigm and a 12-week primary endpoint, as requested by the FDA.
• Initiation of this trial is anticipated in the fourth quarter of 2025.

Key Dates

Recommendation

Keywords

Axsome Therapeutics, AXSM, AXS-14, esreboxetine, fibromyalgia, FDA, New Drug Application, NDA, Refusal to File, RTF, biopharmaceutical, CNS disorders, clinical trial, pain management, central nervous system